ReviewSupportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer2023
The role of dermocosmetics in the management of cancer-related skin toxicities: international expert consensus.
Review in Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 19 citations in OpenAlex.
- Feasibility and safety of combined touch care and aromatherapy in hospitalized patients with thoracic malignancies: A prospective single-arm study.Asia-Pacific journal of oncology nursing · 2026Article
- Best evidence for managing cutaneous immune-related adverse events in cancer: A summary from Chinese and English literature.Asia-Pacific journal of oncology nursing · 2026Review
- Multidisciplinary Strategies to Manage Treatment-Related Dermatologic Toxicity and Improve Quality of Life in Cancer Patients: A Narrative Review.Healthcare (Basel, Switzerland) · 2026Review
- Skin health in oncology: evidence-based skin care for cancer patients.The oncologist · 2026Review
- Managing Skin Side Effects Associated With Oncology Treatments: Asian Perspective on Use of Dermocosmetics.Asia-Pacific journal of clinical oncology · 2026Review
- Prevention and Management of Dermatologic Adverse Events in Patients Treated with Amivantamab Plus Lazertinib.Current oncology (Toronto, Ont.) · 2026Article
- Perspectives on managing skin manifestations in cancer patients: a multidisciplinary mixed-method survey of oncologists and dermatologists.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2026Article
- Post-oncologic skin health: cutaneous recovery and rehabilitation after cancer treatments.Frontiers in oncology · 2026Review
- Targeting Dermatologic Side Effects of Immunotherapy Using Novel Skin Care Products.Journal of Cancer · 2026Article
- Cutaneous and Systemic Complications in Primary CD8+ Aggressive Epidermotropic Cytotoxic T-cell Lymphoma.Cureus · 2025Article
- Rare advanced complication of an infusion port with pocket skin necrosis successfully preserve the port : a case report.Journal of cardiothoracic surgery · 2025Article
- Comment on: "The role of dermocosmetics in the management of cancer-related skin toxicities".Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2025Article
- Exposure Data of Cosmetic Products for Patients Undergoing Cancer Treatment.Journal of cosmetic dermatology · 2025Article
- Dermatologic toxicities related to cancer immunotherapy.Toxicology reports · 2025Article
- Safety Profile ofPharmaceuticals (Basel, Switzerland) · 2025Article
- A questionnaire-based cross-sectional survey of cutaneous adverse events in cancer patients treated with molecular targeted therapy and immunotherapies.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2025Article
- Navigating the Complexities of Radiation Injuries: Therapeutic Principles and Reconstructive Strategies.Journal of personalized medicine · 2024Review
- Management of Skin Toxicities in Cancer Treatment: An Australian/New Zealand Perspective.Cancers · 2024Review
Corrections and comments
- Commented on by
Authors and funding
12 authors at 11 institutions in 6 countries.
Funding
Abstract
Skin toxicities are very common in patients undergoing cancer treatment and have been found to occur with all types of cancer therapeutic interventions (cytotoxic chemotherapy, targeted therapies, immunotherapy, and radiotherapy). Further, skin toxicities can lead to interruption or even discontinuation of anticancer treatment in some patients, translating to suboptimal outcomes. Dermocosmetics (or cosmeceuticals)-defined as skincare solutions incorporating dermatologically active ingredients (beyond vehicle effects) that directly improve symptoms of various skin conditions-are increasingly being used in cancer care to prevent and manage skin toxicities. The active ingredients in these products have a measurable biological action in skin; they typically improve skin integrity (barrier function/hydration and other factors) while relieving skin symptoms. The Association Francophone des Soins Oncologiques de Support (AFSOS) and Multinational Association of Supportive Care in Cancer (MASCC) partnered to select a multidisciplinary group of healthcare professionals involved in the management of patients with cancer and skin toxicities. The group reviewed existing literature and created a summary of recommendations for managing these toxicities through online meetings and communication. In this publication, the group (1) reviews new skin toxicities seen with oncology drugs and (2) evaluates the role of dermocosmetics in improving patient outcomes and minimizing cancer treatment interruptions. We provide general recommendations for initiation and selection of skin care in all oncology patients as well as recommendations for what factors should be considered when using dermocosmetics in specific types of skin toxicities.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.